INV-043 injection / Invion - LARVOL DELTA

Invion Limited…has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, INV043, for the treatment of anal cancer. (finnewsnetwork)

Orphan drug • Anal Carcinoma

Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial (Small Caps) - P1/2 | N=NA | "Invion...has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland....Patients also gave early indications of responding positively to the drug, with an observable reduction in NMSC lesion size at 15 days and 30 days after a single treatment cycle."

P1/2 data • Non-melanoma Skin Cancer